IPSEN SA SP.ADR 1/4/ EO 1 Asset Resilience Ratio

Latest as of December 2025: 0.01%

IPSEN SA SP.ADR 1/4/ EO 1 asset resilience ratio. IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) has an Asset Resilience Ratio of 0.01% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read IPSEN SA SP.ADR 1/4/ EO 1 total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

€1.00 Million
≈ $1.17 Million USD Cash + Short-term Investments

Total Assets

€6.94 Billion
≈ $8.11 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of IPSEN SA SP.ADR 1/4/ EO 1 (2021–2025)

Asset resilience ratio of IPSEN SA SP.ADR 1/4/ EO 1 from 2021 to 2025. This chart shows how IPSEN SA SP.ADR 1/4/ EO 1's Asset Resilience Ratio has changed over time. See I7G0 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down IPSEN SA SP.ADR 1/4/ EO 1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see IPSEN SA SP.ADR 1/4/ EO 1 assets under control.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €1.00 Million 0.01%
Total Liquid Assets €1.00 Million 0.01%

Asset Resilience Insights

  • Limited Liquidity: IPSEN SA SP.ADR 1/4/ EO 1 maintains only 0.01% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

IPSEN SA SP.ADR 1/4/ EO 1 Industry Peers by Asset Resilience Ratio

Compare IPSEN SA SP.ADR 1/4/ EO 1's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Curaleaf Holdings Inc.
TO:CURA
Drug Manufacturers - Specialty & Generic 3.73%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Drug Manufacturers - Specialty & Generic 5.90%
Zhejiang Medicine Co Ltd
SHG:600216
Drug Manufacturers - Specialty & Generic 1.85%
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
Drug Manufacturers - Specialty & Generic 0.40%
Dezhan HealthCare Co Ltd
SHE:000813
Drug Manufacturers - Specialty & Generic 0.09%
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907
Drug Manufacturers - Specialty & Generic 14.54%

IPSEN SA SP.ADR 1/4/ EO 1 Asset Resilience Ratio by Year (2021–2025)

IPSEN SA SP.ADR 1/4/ EO 1 asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for IPSEN SA SP.ADR 1/4/ EO 1.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.01% €1.00 Million
≈ $1.17 Million
€6.94 Billion
≈ $8.11 Billion
0.00pp
2024-12-31 0.02% €1.10 Million
≈ $1.29 Million
€6.44 Billion
≈ $7.53 Billion
-0.15pp
2023-12-31 0.17% €10.60 Million
≈ $12.39 Million
€6.32 Billion
≈ $7.39 Billion
-0.38pp
2022-12-31 0.55% €31.00 Million
≈ $36.24 Million
€5.61 Billion
≈ $6.56 Billion
-0.30pp
2021-12-31 0.85% €42.40 Million
≈ $49.57 Million
€4.99 Billion
≈ $5.83 Billion
--
pp = percentage points

About IPSEN SA SP.ADR 1/4/ EO 1

F:I7G0 Germany Drug Manufacturers - Specialty & Generic
Market Cap
$15.72 Billion
€13.45 Billion EUR
Market Cap Rank
#1778 Global
#382 in Germany
Share Price
€40.80
Change (1 day)
+3.03%
52-Week Range
€24.40 - €42.60
All Time High
€42.60
About

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more